Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy
Aims Exogenous atrial natriuretic peptide (ANP) may be a logical treatment for heart failure (HF) patients with ANP deficiency. Lower ANP concentrations may result from HF with preserved ejection fraction (HFpEF), which also results in lower brain natriuretic peptide levels in HFpEF relative to HF w...
Gespeichert in:
| Veröffentlicht in: | ESC Heart Failure 2020-12, Vol.7 (6), p.4172-4181 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4181 |
|---|---|
| container_issue | 6 |
| container_start_page | 4172 |
| container_title | ESC Heart Failure |
| container_volume | 7 |
| creator | Matsumoto, Shingo Nakazawa, Gaku Ohno, Yohei Ishihara, Mai Sakai, Katsuaki Nakamura, Norihito Murakami, Tsutomu Natsumeda, Makoto Kabuki, Takayuki Shibata, Atsushi Kida, Keisuke Konishi, Masaaki Ishii, Shunsuke Ikeda, Takanori Ikari, Yuji |
| description | Aims
Exogenous atrial natriuretic peptide (ANP) may be a logical treatment for heart failure (HF) patients with ANP deficiency. Lower ANP concentrations may result from HF with preserved ejection fraction (HFpEF), which also results in lower brain natriuretic peptide levels in HFpEF relative to HF with reduced ejection fraction (HFrEF), although clinical features regarding circulating ANP in HFpEF and HFrEF have not been fully investigated during acute HF. Here, we characterized the differential regulation of circulating ANP and the efficacy of exogenous ANP (carperitide) in patients with acute HF, especially HFpEF.
Methods and results
Serum ANP levels before treatment and the diuretic effect of 0.0125 μg/kg/min of carperitide alone for the first 6 h were prospectively evaluated in 113 patients with acute HF who were divided into two groups: HFpEF vs. HFrEF. We mainly analysed the impact of baseline ANP levels and the presence of HFpEF on the diuretic effect of exogenous ANP. There was an inverse relationship between ANP levels and the diuretic effect of exogenous ANP (r2 = 0.19, P |
| doi_str_mv | 10.1002/ehf2.13042 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_33037750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6755812e39584fbebad29a2314e3afe1</doaj_id><sourcerecordid>2628048928</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5422-4700a62936c2cee349437b56d1deba4cf0d080b49aa5a5dc8c4651a0e0273fa43</originalsourceid><addsrcrecordid>eNqNkk1vEzEQhlcIRKvSCz8AWeKCQCn-3A8OSChKaaVKXOBsTbzjxNFmvXi9Lflb_EK82RC1HCJOtsbPvDPjebPsNaNXjFL-EdeWXzFBJX-WnXOq1EyVnD9_dD_LLvt-QyllKmeKy5fZmRBUFIWi59nvhbXOgNkRbwn-8its_dATiMFBQ9rxHAJGZ0iHXXQ1EteSDqLDNvbkwcU1WSOESCy4JpFTqAvYY7jHmuAGTXS-JTbA_vKJ1Jgqpvyp5olK0NYkYNeAwW0qR-IaA3S7V9kLC02Pl4fzIvtxvfg-v5ndfft6O_9yNzNKcj6TBaWQ80rkhhtEISspiqXKa1bjEqSxtKYlXcoKQIGqTWlkrhhQpLwQFqS4yG4n3drDRnfBbSHstAen9wEfVjoN7kyDOi-UKhlHUalS2mXSr3kFXDCJAiyypPV50uqG5RZrk8YJ0DwRffrSurVe-XudtiTLiieBdweB4H8O2Ee9db3BpoEW08I0l7KqciEKkdC3_6AbP4Q2fZXmOS_pqFeepGTBCqYYrRL1fqJM8H0f0B5bZlSP_tOj__Tefwl-83jII_rXbQkoJ-ABl972exPgEUsOVUVRCa7oaNa5izAaZu6HNqbUD_-fmmh2oF2DuxM968XNNZ-6_wPOWglB</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471715109</pqid></control><display><type>article</type><title>Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Matsumoto, Shingo ; Nakazawa, Gaku ; Ohno, Yohei ; Ishihara, Mai ; Sakai, Katsuaki ; Nakamura, Norihito ; Murakami, Tsutomu ; Natsumeda, Makoto ; Kabuki, Takayuki ; Shibata, Atsushi ; Kida, Keisuke ; Konishi, Masaaki ; Ishii, Shunsuke ; Ikeda, Takanori ; Ikari, Yuji</creator><creatorcontrib>Matsumoto, Shingo ; Nakazawa, Gaku ; Ohno, Yohei ; Ishihara, Mai ; Sakai, Katsuaki ; Nakamura, Norihito ; Murakami, Tsutomu ; Natsumeda, Makoto ; Kabuki, Takayuki ; Shibata, Atsushi ; Kida, Keisuke ; Konishi, Masaaki ; Ishii, Shunsuke ; Ikeda, Takanori ; Ikari, Yuji</creatorcontrib><description>Aims
Exogenous atrial natriuretic peptide (ANP) may be a logical treatment for heart failure (HF) patients with ANP deficiency. Lower ANP concentrations may result from HF with preserved ejection fraction (HFpEF), which also results in lower brain natriuretic peptide levels in HFpEF relative to HF with reduced ejection fraction (HFrEF), although clinical features regarding circulating ANP in HFpEF and HFrEF have not been fully investigated during acute HF. Here, we characterized the differential regulation of circulating ANP and the efficacy of exogenous ANP (carperitide) in patients with acute HF, especially HFpEF.
Methods and results
Serum ANP levels before treatment and the diuretic effect of 0.0125 μg/kg/min of carperitide alone for the first 6 h were prospectively evaluated in 113 patients with acute HF who were divided into two groups: HFpEF vs. HFrEF. We mainly analysed the impact of baseline ANP levels and the presence of HFpEF on the diuretic effect of exogenous ANP. There was an inverse relationship between ANP levels and the diuretic effect of exogenous ANP (r2 = 0.19, P < 0.001). Patients with HFpEF had lower ANP levels (P < 0.001) and a greater diuretic effect of exogenous ANP than patients HFrEF (P < 0.001). HFpEF was an independent predictor of greater diuretic effect of exogenous ANP (P = 0.003), as with a lower baseline ANP level (P = 0.004).
Conclusions
Patients with HFpEF might have an aspect of ANP deficiency and represent a promising therapeutic target for modulating circulating ANP.</description><identifier>ISSN: 2055-5822</identifier><identifier>EISSN: 2055-5822</identifier><identifier>DOI: 10.1002/ehf2.13042</identifier><identifier>PMID: 33037750</identifier><language>eng</language><publisher>SAN FRANCISCO: Wiley</publisher><subject>Acute heart failure (AHF) ; Atrial fibrillation (AF) ; Blood pressure ; Brain natriuretic peptide (BNP) ; Cardiac & Cardiovascular Systems ; Cardiovascular System & Cardiology ; Carperitide ; Clinical trials ; Diuretics ; Ejection fraction ; Heart failure ; Hospitalization ; Left atrial dysfunction ; Life Sciences & Biomedicine ; Obesity ; Original ; Original s ; Patients ; Peptides ; Plasma ; Science & Technology ; Urine ; Variables</subject><ispartof>ESC Heart Failure, 2020-12, Vol.7 (6), p.4172-4181</ispartof><rights>2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology</rights><rights>2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>12</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000577932500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c5422-4700a62936c2cee349437b56d1deba4cf0d080b49aa5a5dc8c4651a0e0273fa43</citedby><cites>FETCH-LOGICAL-c5422-4700a62936c2cee349437b56d1deba4cf0d080b49aa5a5dc8c4651a0e0273fa43</cites><orcidid>0000-0001-9701-8730</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754892/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754892/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,1418,2103,2115,11567,27929,27930,28253,45579,45580,46057,46481,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33037750$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsumoto, Shingo</creatorcontrib><creatorcontrib>Nakazawa, Gaku</creatorcontrib><creatorcontrib>Ohno, Yohei</creatorcontrib><creatorcontrib>Ishihara, Mai</creatorcontrib><creatorcontrib>Sakai, Katsuaki</creatorcontrib><creatorcontrib>Nakamura, Norihito</creatorcontrib><creatorcontrib>Murakami, Tsutomu</creatorcontrib><creatorcontrib>Natsumeda, Makoto</creatorcontrib><creatorcontrib>Kabuki, Takayuki</creatorcontrib><creatorcontrib>Shibata, Atsushi</creatorcontrib><creatorcontrib>Kida, Keisuke</creatorcontrib><creatorcontrib>Konishi, Masaaki</creatorcontrib><creatorcontrib>Ishii, Shunsuke</creatorcontrib><creatorcontrib>Ikeda, Takanori</creatorcontrib><creatorcontrib>Ikari, Yuji</creatorcontrib><title>Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy</title><title>ESC Heart Failure</title><addtitle>ESC HEART FAIL</addtitle><addtitle>ESC Heart Fail</addtitle><description>Aims
Exogenous atrial natriuretic peptide (ANP) may be a logical treatment for heart failure (HF) patients with ANP deficiency. Lower ANP concentrations may result from HF with preserved ejection fraction (HFpEF), which also results in lower brain natriuretic peptide levels in HFpEF relative to HF with reduced ejection fraction (HFrEF), although clinical features regarding circulating ANP in HFpEF and HFrEF have not been fully investigated during acute HF. Here, we characterized the differential regulation of circulating ANP and the efficacy of exogenous ANP (carperitide) in patients with acute HF, especially HFpEF.
Methods and results
Serum ANP levels before treatment and the diuretic effect of 0.0125 μg/kg/min of carperitide alone for the first 6 h were prospectively evaluated in 113 patients with acute HF who were divided into two groups: HFpEF vs. HFrEF. We mainly analysed the impact of baseline ANP levels and the presence of HFpEF on the diuretic effect of exogenous ANP. There was an inverse relationship between ANP levels and the diuretic effect of exogenous ANP (r2 = 0.19, P < 0.001). Patients with HFpEF had lower ANP levels (P < 0.001) and a greater diuretic effect of exogenous ANP than patients HFrEF (P < 0.001). HFpEF was an independent predictor of greater diuretic effect of exogenous ANP (P = 0.003), as with a lower baseline ANP level (P = 0.004).
Conclusions
Patients with HFpEF might have an aspect of ANP deficiency and represent a promising therapeutic target for modulating circulating ANP.</description><subject>Acute heart failure (AHF)</subject><subject>Atrial fibrillation (AF)</subject><subject>Blood pressure</subject><subject>Brain natriuretic peptide (BNP)</subject><subject>Cardiac & Cardiovascular Systems</subject><subject>Cardiovascular System & Cardiology</subject><subject>Carperitide</subject><subject>Clinical trials</subject><subject>Diuretics</subject><subject>Ejection fraction</subject><subject>Heart failure</subject><subject>Hospitalization</subject><subject>Left atrial dysfunction</subject><subject>Life Sciences & Biomedicine</subject><subject>Obesity</subject><subject>Original</subject><subject>Original s</subject><subject>Patients</subject><subject>Peptides</subject><subject>Plasma</subject><subject>Science & Technology</subject><subject>Urine</subject><subject>Variables</subject><issn>2055-5822</issn><issn>2055-5822</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>AOWDO</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNqNkk1vEzEQhlcIRKvSCz8AWeKCQCn-3A8OSChKaaVKXOBsTbzjxNFmvXi9Lflb_EK82RC1HCJOtsbPvDPjebPsNaNXjFL-EdeWXzFBJX-WnXOq1EyVnD9_dD_LLvt-QyllKmeKy5fZmRBUFIWi59nvhbXOgNkRbwn-8its_dATiMFBQ9rxHAJGZ0iHXXQ1EteSDqLDNvbkwcU1WSOESCy4JpFTqAvYY7jHmuAGTXS-JTbA_vKJ1Jgqpvyp5olK0NYkYNeAwW0qR-IaA3S7V9kLC02Pl4fzIvtxvfg-v5ndfft6O_9yNzNKcj6TBaWQ80rkhhtEISspiqXKa1bjEqSxtKYlXcoKQIGqTWlkrhhQpLwQFqS4yG4n3drDRnfBbSHstAen9wEfVjoN7kyDOi-UKhlHUalS2mXSr3kFXDCJAiyypPV50uqG5RZrk8YJ0DwRffrSurVe-XudtiTLiieBdweB4H8O2Ee9db3BpoEW08I0l7KqciEKkdC3_6AbP4Q2fZXmOS_pqFeepGTBCqYYrRL1fqJM8H0f0B5bZlSP_tOj__Tefwl-83jII_rXbQkoJ-ABl972exPgEUsOVUVRCa7oaNa5izAaZu6HNqbUD_-fmmh2oF2DuxM968XNNZ-6_wPOWglB</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Matsumoto, Shingo</creator><creator>Nakazawa, Gaku</creator><creator>Ohno, Yohei</creator><creator>Ishihara, Mai</creator><creator>Sakai, Katsuaki</creator><creator>Nakamura, Norihito</creator><creator>Murakami, Tsutomu</creator><creator>Natsumeda, Makoto</creator><creator>Kabuki, Takayuki</creator><creator>Shibata, Atsushi</creator><creator>Kida, Keisuke</creator><creator>Konishi, Masaaki</creator><creator>Ishii, Shunsuke</creator><creator>Ikeda, Takanori</creator><creator>Ikari, Yuji</creator><general>Wiley</general><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9701-8730</orcidid></search><sort><creationdate>202012</creationdate><title>Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy</title><author>Matsumoto, Shingo ; Nakazawa, Gaku ; Ohno, Yohei ; Ishihara, Mai ; Sakai, Katsuaki ; Nakamura, Norihito ; Murakami, Tsutomu ; Natsumeda, Makoto ; Kabuki, Takayuki ; Shibata, Atsushi ; Kida, Keisuke ; Konishi, Masaaki ; Ishii, Shunsuke ; Ikeda, Takanori ; Ikari, Yuji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5422-4700a62936c2cee349437b56d1deba4cf0d080b49aa5a5dc8c4651a0e0273fa43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acute heart failure (AHF)</topic><topic>Atrial fibrillation (AF)</topic><topic>Blood pressure</topic><topic>Brain natriuretic peptide (BNP)</topic><topic>Cardiac & Cardiovascular Systems</topic><topic>Cardiovascular System & Cardiology</topic><topic>Carperitide</topic><topic>Clinical trials</topic><topic>Diuretics</topic><topic>Ejection fraction</topic><topic>Heart failure</topic><topic>Hospitalization</topic><topic>Left atrial dysfunction</topic><topic>Life Sciences & Biomedicine</topic><topic>Obesity</topic><topic>Original</topic><topic>Original s</topic><topic>Patients</topic><topic>Peptides</topic><topic>Plasma</topic><topic>Science & Technology</topic><topic>Urine</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsumoto, Shingo</creatorcontrib><creatorcontrib>Nakazawa, Gaku</creatorcontrib><creatorcontrib>Ohno, Yohei</creatorcontrib><creatorcontrib>Ishihara, Mai</creatorcontrib><creatorcontrib>Sakai, Katsuaki</creatorcontrib><creatorcontrib>Nakamura, Norihito</creatorcontrib><creatorcontrib>Murakami, Tsutomu</creatorcontrib><creatorcontrib>Natsumeda, Makoto</creatorcontrib><creatorcontrib>Kabuki, Takayuki</creatorcontrib><creatorcontrib>Shibata, Atsushi</creatorcontrib><creatorcontrib>Kida, Keisuke</creatorcontrib><creatorcontrib>Konishi, Masaaki</creatorcontrib><creatorcontrib>Ishii, Shunsuke</creatorcontrib><creatorcontrib>Ikeda, Takanori</creatorcontrib><creatorcontrib>Ikari, Yuji</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>ESC Heart Failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsumoto, Shingo</au><au>Nakazawa, Gaku</au><au>Ohno, Yohei</au><au>Ishihara, Mai</au><au>Sakai, Katsuaki</au><au>Nakamura, Norihito</au><au>Murakami, Tsutomu</au><au>Natsumeda, Makoto</au><au>Kabuki, Takayuki</au><au>Shibata, Atsushi</au><au>Kida, Keisuke</au><au>Konishi, Masaaki</au><au>Ishii, Shunsuke</au><au>Ikeda, Takanori</au><au>Ikari, Yuji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy</atitle><jtitle>ESC Heart Failure</jtitle><stitle>ESC HEART FAIL</stitle><addtitle>ESC Heart Fail</addtitle><date>2020-12</date><risdate>2020</risdate><volume>7</volume><issue>6</issue><spage>4172</spage><epage>4181</epage><pages>4172-4181</pages><issn>2055-5822</issn><eissn>2055-5822</eissn><abstract>Aims
Exogenous atrial natriuretic peptide (ANP) may be a logical treatment for heart failure (HF) patients with ANP deficiency. Lower ANP concentrations may result from HF with preserved ejection fraction (HFpEF), which also results in lower brain natriuretic peptide levels in HFpEF relative to HF with reduced ejection fraction (HFrEF), although clinical features regarding circulating ANP in HFpEF and HFrEF have not been fully investigated during acute HF. Here, we characterized the differential regulation of circulating ANP and the efficacy of exogenous ANP (carperitide) in patients with acute HF, especially HFpEF.
Methods and results
Serum ANP levels before treatment and the diuretic effect of 0.0125 μg/kg/min of carperitide alone for the first 6 h were prospectively evaluated in 113 patients with acute HF who were divided into two groups: HFpEF vs. HFrEF. We mainly analysed the impact of baseline ANP levels and the presence of HFpEF on the diuretic effect of exogenous ANP. There was an inverse relationship between ANP levels and the diuretic effect of exogenous ANP (r2 = 0.19, P < 0.001). Patients with HFpEF had lower ANP levels (P < 0.001) and a greater diuretic effect of exogenous ANP than patients HFrEF (P < 0.001). HFpEF was an independent predictor of greater diuretic effect of exogenous ANP (P = 0.003), as with a lower baseline ANP level (P = 0.004).
Conclusions
Patients with HFpEF might have an aspect of ANP deficiency and represent a promising therapeutic target for modulating circulating ANP.</abstract><cop>SAN FRANCISCO</cop><pub>Wiley</pub><pmid>33037750</pmid><doi>10.1002/ehf2.13042</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9701-8730</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2055-5822 |
| ispartof | ESC Heart Failure, 2020-12, Vol.7 (6), p.4172-4181 |
| issn | 2055-5822 2055-5822 |
| language | eng |
| recordid | cdi_pubmed_primary_33037750 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley-Blackwell Open Access Titles; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Wiley Online Library All Journals; PubMed Central |
| subjects | Acute heart failure (AHF) Atrial fibrillation (AF) Blood pressure Brain natriuretic peptide (BNP) Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Carperitide Clinical trials Diuretics Ejection fraction Heart failure Hospitalization Left atrial dysfunction Life Sciences & Biomedicine Obesity Original Original s Patients Peptides Plasma Science & Technology Urine Variables |
| title | Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T15%3A26%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20exogenous%20atrial%20natriuretic%20peptide%20in%20patients%20with%20heart%20failure%20with%20preserved%20ejection%20fraction:%20deficiency%20of%20atrial%20natriuretic%20peptide%20and%20replacement%20therapy&rft.jtitle=ESC%20Heart%20Failure&rft.au=Matsumoto,%20Shingo&rft.date=2020-12&rft.volume=7&rft.issue=6&rft.spage=4172&rft.epage=4181&rft.pages=4172-4181&rft.issn=2055-5822&rft.eissn=2055-5822&rft_id=info:doi/10.1002/ehf2.13042&rft_dat=%3Cproquest_pubme%3E2628048928%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471715109&rft_id=info:pmid/33037750&rft_doaj_id=oai_doaj_org_article_6755812e39584fbebad29a2314e3afe1&rfr_iscdi=true |